1276197-58-0C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O.OQTAOMKOIBXZKND-PPHPATTJSA-NCarbidopa is the hydrate of 3-(3,4-dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa. It has a role as an antiparkinson drug, a dopaminergic agent, an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor and an antidyskinesia agent. It is a member of hydrazines, a monocarboxylic acid, a member of catechols and a hydrate. It contains a carbidopa (anhydrous).
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (60.2%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 108 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
VerwendenLabelled analogue of (S)-(-)-Carbidopa, a peripheral decarboxylase inhibitor, commonly used in combination with L-DOPA (D533751) for the treatment of Parkinsonism. S(-)-Carbidopa has also been shown to prolong the elimination half-life of L-DOPA from blood plasma and skeletal muscle.
Wird geladen…
Wird geladen…
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
1276197-58-0CHEBI:3395